Rsip Vision Ltd. has maintained its momentum with a couple of new software module releases, one focused on sports medicine and another for robotic assisted surgery. The most recent release is a software module that enables deep learning-based segmentation of joint cartilage from MRI scans of hips, knees and ankles. “It's about using AI-based auto segmentation to provide clinically valuable measurements,” Moshe Safran, the CEO of Rsip Vision U.S., told BioWorld.
The Hong Kong Polytechnic University (PolyU) has developed new side-hole polymer optical fiber sensors, which can be used in multiple medical treatments without the drawbacks of other optical fibers used in the past. The biocompatible plastic sensors are humidity insensitive, supple and shatter-resistant. This means they can be used in various medical settings, ranging from surgical instrumentation, diagnostics to imaging equipment and sensor-based medical devices.
An artificial intelligence (AI)-powered tool invented by researchers from a trio of Singaporean institutions could speed up the diagnosis of cardiovascular diseases. The innovation uses electrocardiograms (ECGs) to diagnose coronary artery disease, myocardial infarction and congestive heart failure.
A new regulatory agreement could give Indonesia greater access to newer drugs and Chinese companies greater market share in Southeast Asia’s largest market.
A new regulatory agreement could give Indonesia greater access to newer drugs and Chinese companies greater market share in Southeast Asia’s largest market.
Shenzhen Mindray Bio-Medical Electronics Co. Ltd. plans to release a couple of new imaging solutions this month as part of continued and rapid growth in its home market and globally. The first to be unveiled by the Shenzhen, China-based company is the Resona I9, its latest general imaging diagnostic ultrasound system.
Kahr Medical Ltd.’s $46.5 million financing provides runway to advance its multifunctional immunotherapeutic pipeline. The proceeds will be used to for clinical development of its lead asset, DSP-107, a first-in-class CD47x41BB targeting fusion protein to treat solid tumors and blood cancers through multiple phase I/II studies.
The Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF) has raised more than half of its proposed ¥2 billion (US$313 million) round. “The second fund, GIBF2, will focus on Israeli and European biotechnology companies, which are developing innovative drugs and are in phase II to III clinical trials,” Avner Lushi, the CEO and co-founder of the GIBF, told BioWorld. The Chinese RMB fund is managed by The Guangzhou Elim Biotech Industry Venture Capital Management Company, which is controlled by a group of prominent Israeli professionals.
HONG KONG – Singapore authorities have given provisional approval for a locally developed breath test for COVID-19. The test is developed by Breathonix Pte Ltd., a spin-off company from the National University of Singapore through its Graduate Research Innovation Program. The company said its Brefence Go COVID-19 breath test system was the first test of its kind to secure provisional authorization in Singapore.
The Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF) has raised more than half of its proposed ¥2 billion (US$313 million) round. “The second fund, GIBF2, will focus on Israeli and European biotechnology companies, which are developing innovative drugs and are in phase II to III clinical trials,” Avner Lushi, the CEO and co-founder of the GIBF, told BioWorld.
